Short answer
Aurinia Pharmaceuticals Inc. (AUPH) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $84M (up 13.9% year over year) with net income of $32M.
Q3 2026 key financials · XBRL
- Revenue
- $84M
- +13.9% YoY · +0.6% QoQ
- Net income
- $32M
- +0.5% YoY · −15.3% QoQ
- Operating margin
- 42.3%
- EPS (diluted)
- $0.23
- +0.0% YoY · −17.9% QoQ
Source: XBRL data from the Aurinia Pharmaceuticals Inc. (AUPH) Q3 2026 10-Q on SEC EDGAR. USD.
Aurinia Pharmaceuticals Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $83.7M, up 14% YoY from $73.5M, driven by LUPKYNIS sales
- Gross margin 90% vs 89% YoY, net income $31.7M vs $31.6M
- LUPKYNIS sales $79.4M, up 12% YoY from $70.6M
- Cash, restricted cash and investments $486.9M vs $398.0M at December 31, 2025
- Operating cash flow $131.5M, up 46% YoY; share repurchases $74.9M for 5.0M shares
Risk Factors
- No material risk-factor changes since the December 31, 2025 Form 10-K
- Carried-forward financial-performance risks could cause actual results to differ materially from expectations
- Additional currently immaterial or unknown risks could materially affect future results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aurinia Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.